Midterm results with hepatectomy after preoperative chemotherapy in hepatoblastoma

Department of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi, 110029, India.
Pediatric Surgery International (Impact Factor: 1.06). 06/2005; 21(5):364-8. DOI: 10.1007/s00383-005-1381-1
Source: PubMed

ABSTRACT We evaluated the results of surgical treatment for hepatoblastoma in infants and children after intensive preoperative chemotherapy, with special reference to histology and extent of liver involvement. The clinical features of 10 children with hepatoblastoma were reviewed regarding response to neoadjuvant chemotherapy, histological subtypes, extent of hepatectomy, operative complications, and prognosis. Response to chemotherapy was measured by volumetric assessment of tumour size by computed tomography scan. Cisplatin and Adriamycin (PLADO regime) up to three cycles markedly reduced the tumour volume on computed tomography (mean regression rate 65.9%); alpha-foetoprotein (AFP) levels also decreased from an initial mean of 16,116.4 ng/ml to 2,050.9 ng/ml. Five patients underwent right hepatectomy, two had right trisegmentectomy, two had left hepatectomy, and one had left trisegmentectomy. Histopathology of resected specimens revealed foetal histology in four patients, poorly differentiated (anaplastic) subtype in three, and mixed histology with mesenchymal components and osteoid formation in three. There was 100% resectability including six unresectable tumours (prechemotherapy). Moreover, hepatic resection tended to be less invasive in patients whose tumours had been much reduced after preoperative chemotherapy. Preoperative administration of cisplatin and Adriamycin reduces the tumour size significantly so that a safe radical hepatectomy can be performed. It also allows early administration of postoperative chemotherapy. Although overall good results were obtained with the current protocol, we also document our experience of unfavourable outcomes in patients with bilobar tumours (despite trisegmentectomy), patients with tumours showing poor response to neoadjuvant chemotherapy, and patients with anaplastic histology. Overall, at a 60-month follow-up we report an 80% survival rate by a combined approach.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The eigenvalue placement of controllable generalized systems of the form E ˆ x ˙( t )= A ˆ x ( t )+ B ˆ u ( t ) by constant-ratio proportional derivative (CRPD) feedback control of the form u ( t )= K ˆ(ρ x ˆ( t )- x ( t )+ w ( t )) is discussed. The problem is an extension of the traditional state feedback control law, which is the case of E ˆ= I and ρ=0. A controllable canonical form and its transformation matrices are used to solve this problem. Based on the developed canonical transformation, pole assignment of generalized systems can be implemented easily. The development of the authors' method depends crucially on the properties of standard form generalized systems. One illustrative example is included
    Circuits and Systems, 1992., Proceedings of the 35th Midwest Symposium on; 09/1992
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Though surgical resection is the main stay of treatment for childhood hepatoblastoma (HB), many are unsuitable for radical surgery at diagnosis due to extensive intrahepatic and/or extra hepatic disease. We report experience in five patients of HB from a single institution (2001-2005) with preoperative Neoadjuvant chemotherapy (NACT) followed by surgery. Three patients received cisplatin, doxorubicin; and two cisplatin / vincristine /5-fluorouracil. All showed more than 50% reduction in tumor size confirmed by CT scan. Hepatic resection R0 was performed in all. There was no chemotherapy related toxicity nor post surgical morbidity or mortality. All are disease free at median follow up of 4 years. NACT produces adequate down staging of the HB with acceptable toxicity. Though cisplatin with doxorubicin produced good results, new protocol with cisplatin, vincristine and 5FU is promising without cardiotoxicity.
    The Indian Journal of Pediatrics 09/2006; 73(8):735-7. DOI:10.1007/BF02898456 · 0.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatoblastomas are the most common liver tumours in children. However, they are rare as compared to other solid malignancies. Thus, there is a need to integrate data from surgical centers around the world to provide a clearer view on the outcomes of multidisciplinary management of these tumours. We set out to retrospectively review our experience of patients with surgically resected hepatoblastomas looking at primary and secondary outcomes. Children diagnosed with hepatoblastoma and managed surgically (along with chemotherapy) at a single institution between 1 January 2000 and 31 May 2007, were analyzed. Out of the 18 patients, there were 12 male and 6 female patients. The median age was 18 months (range 8-72). A palpable mass in abdomen was the presenting symptom in 88% patients. Sixteen patients (88.8%) underwent major liver resection. Sixteen patients (88.8%) received preoperative chemotherapy. Complete gross resection (stage I and II) was achieved in all 18 patients (100%). The mortality and morbidity rates were 0 and 11.2%, respectively. The 80-month disease-free survival was 67%. This series, the largest from India in terms of surgical resections for hepatoblastoma, reaffirms that major liver resection can be performed with minimal perioperative mortality and morbidity and that the use of chemotherapy has definitely helped in down staging tumours for liver resection.
    Pediatric Surgery International 08/2008; 24(7):799-802. DOI:10.1007/s00383-008-2169-x · 1.06 Impact Factor
Show more